Insider Filings: MedMen, iAnthus, 4Front Ventures

In this week's post, we look at insider filings -- both on the buy and sell side -- that have been filed in the past 7 days from company insiders of MedMen, iAnthus, and 4Front Ventures. Please note that all amounts are listed in United States Dollars ($USD) unless otherwise noted.

Lastly, if you would like to learn more about each company, please click through their company logo to be taken to their company profile page where we detail specific information such as fully diluted market cap, share count, quarterly financials, and also extrapolate on their licenses by way of a highly-detailed footprint map.

On 08/21/19, Andrew Modlin, Co-Founder and President of MedMen, bought a total of 198,018 shares in two separate transactions. The net total of these transactions was roughly $406,000.

Hadley Ford, CEO and Director of iAnthus Capital, sold a total of 30,000 shares at an average price of ~$3.32 ($CAD) on 09/03/19. In total, these transactions netted Mr. Ford roughly $100,000.

In a bevvy of various transactions over 2 days (09/04 - 09/05), Andrew Thut, Chief Investment Officer of 4Front Ventures, purchased an aggregate total of 145,000 shares, at an average price of $0.62, on the open markets.

Additionally, between 09/03 and 09/04, 4Front's Chief Financial Officer, Brad Kotansky, purchased a total of 30,000 shares at an average price of $0.60.

And, lastly, a company President (and former COO of Cannex), Leo Gontmakher, purchased 15,000 shares @ $0.66.

Thank you for reading. Please consider following us on Twitter for more content like this, and to stay updated with both the website and all of the companies featured herein.

News & Editorials


carefully cultivating news and data on the top US-based cannabis companies